2. Literature Review
2.1. Travel Behavior
A normalidade de distribuição de todas as variáveis foi avaliada utilizando- se o teste de Kolmogorov–Smirnov. Os resultados foram expressos como média ± desvio padrão para variáveis com distribuição normal, mediana (intervalo interquartil, p25-p75) para variáveis com distribuição não-paramétrica e freqüências simples para variáveis categóricas.
A significância das diferenças entre grupos foi determinada utilizando- se os testes t de Student, Mann-Whitney e análise de variância (ANOVA), conforme indicado. Comparações de freqüências foram analisadas pelo teste qui-quadrado e correlações avaliadas pelo teste de correlação de Pearson. Para todas as análises o valor de P < 0.05 foi considerado estatisticamente significativo.
A análise estatística dos resultados foi realizada usando-se o software estatístico SPSS versão 13.0 para Windows (SPSS, Chicago IL).
6 REFERÊNCIAS
1Rother ET, Braga MER, editores. Como elaborar sua tese: estrutura e referências. São
Paulo:2001.86p.
2International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted
to Biomedical Journals. Ann Intern Med 1997;126:36-47.
Adashi, EY. Insulin and related peptides in hyperandrogenism. Clin Obstet Gynecol 1991;34:72-81.
Albuquerque RM, Cecatti JG, Hardy EE, Faundes A. Causas e fatores associados à mortalidade de mulheres em idade reprodutiva em Recife, Brasil. Cad Saúde Pública 1998;14 supl1:41-48.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35
Araujo LF, de Matos Soeiro A, Fernandes JL, Pesaro AE, Serrano CV Jr. Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment. Vasc Health Risk Manag 2006;2:465-75.
Archard C, Thiers J. Le virilisme pilaire et son association a l’insuffisance glycolytique (Diabete des femme a barbe). Bull Acad Natl Med 1921;86: 51.
Este trabalho foi elaborado seguindo as normas adotadas pelo Programa de Pós-graduação em Ciências da Saúde da Universidade Federal do Rio Grande do Norte1.
As citações bibliográficas no texto foram feitas de acordo com o Sistema Alfabético, mencionando-se o autor seguido da data de publicação, com a listagem das referências em ordem alfabética1.
As referências bibliográficas foram normatizadas de acordo com o International Committee
of Medical Journal Editors2 (Updated Feb 2006: http://www.icmje.org/index.html)
Ärnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969-75.
Azevedo GD, Duarte JMBP, Souza MO, Costa-e-Silva TDN, Soares EMM, Maranhão TMO. Menstrual cycle irregularity and risk for future cardiovascular disease. Arq Bras Endocrinol Metab 2006;50:876-83.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO.The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril Fertil Steril 2005;83:1343-6. 24.
Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999;22:307-13.
Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol 2006;65:137-45.
Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993;59:323-31.
Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction. J Nephrol 2007;20:10-4.
Bloomgarden ZT. Insulin resistance: causes and consequences. Int Rev Neurobiol 2005a;65:1-24.
Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care 2005b;28:1821-30.
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.
Cara JF, Rosenfield, RL. Somatomedin C Insulin like growth factor (IGF-I) enhances LH binding to rat intersticial cells. Clin Res 1988;36:901.
Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-5. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-
ASRM guidelines. Minerva Ginecol 2004; 56:1-6.
Carvalheiro CDG, Manço ARX. Mortalidade feminina no período reprodutivo em localidade urbana da Região Sudeste do Brasil. Evolução nos últimos 20 anos. Revista de Saúde Pública1992;26:239-45.
Cohen A, McCarthy D, Stoff J. Direct hemodynamic effect of insulin in the isolated perfused kidney. Am J Physiol Renal Fluid 1989;257:580-5.
Dewailly D, Cortet-Rudelli C, Deroubaix-Allardi D. Definition, clinical manifestations, and prevalence of PCOS- In: Azziz R, Nestler JE, Dewailly D, editors. Androgens Excess Disorders Women. New York: Raven Publishers, 1997. p.259-68.
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
Diamanti-Kandarakis E, Spina G, Chryssa K, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86:3595-98.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415- 28.
Ehrmann DA, Barnes RB, Rosenfield RI, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141 -146.
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Diabetes Care 2006;22:141-6.
Erhmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensivity
and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-7.
Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5-20.
Faundes A, Parpinelli MA, Cecatti JG. Mortalidade de mulheres em idade fértil em Campinas, São Paulo (1985-1994). Cad Saúde Pública 2000;16:671-679.
Ferriman DG, Gallwey JD. Clinical assestment of body hair growth in women. J Clin Endocrino Metab 1961;21:1440-7.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 2002;287:356–9.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78.
Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-61.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158-65.
Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-15.
Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005;1:100-10.
Heron MP, Smith BL. Deaths: leading causes for 2003. Natl Vital Stat Rep 2007;15;55:1-92.
Homburg R. Involvement of growth factors in the pathophysiology of polycystic ovary syndrome. Gynecol Endocrinol 1998;12:391-7.
Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000;35:898-903.
Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:53-8.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;6;110:32-5.
Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46:33-7.
Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med. 2006;260:231-7.
Klein R, Barrett-Connor EL, Blunt BA, Wingard DL. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed NIDDM. Diabetes Care 1991;14:914-18.
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascular dysfunction in women with polycystic ovary syndrome. Hum Reprod 2005;20:3219-24.
Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol 2004;24:613-21.
Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006;15:631-6.
Laws A, Reaven GM. Insulin resistance and risk factors for coronary heart disease. Baillieres Clin Endocrinol Metab 1993:7:1063-78.
Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-54. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful
measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-8.
Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 2003;24:302–12.
Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z. Evaluation of endothelial function in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007; [Epub ahead of print].
Marasciulo FL, Montagnani M, Potenza MA. . Endothelin-1: the yin and yang on vascular function. Curr Med Chem 2006;13:1655-65 .
Medina MA, Amores-Sanchez MI. Homocysteine: an emergent cardiovascular risk factor? Eur J Clin Invest 2000;30:754-62.
Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326:22-29.
Nam Menke M, Strauss JF 3rd. Genetics of polycystic ovarian syndrome. Clin Obstet Gynecol 2007;50:188-204.
Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987;10:414-18.
Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997;15:111-22.
Paradisi R, Venturosi, R, Capelli, M. Effect of alpha-adrenergic blockade on pulsatile LH, FSH and PRL secretion in polycystic ovary syndrome. J Clin Endocr Metab 1987;65:841-6.
Petermann TS, Castillo T, Candia M. Hiperandrogenemia e Insulinorresistencia. Bol Hosp San Juan de Dios 1995;42:117-24.
Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000;49:748-52.
Pimenta W, Mitrakou A, Yki-Järvinen H, Daily G, Gerich J. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance. Diabetic Med 1996; 13:S33-S36.
Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007;3:46-56.
Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
Reaven GM. Role of insulin resistance in human disease: Banting lecture. Diabetes 1988;37:1595-607.
Ritz E, Orth SR. Nefropathy in pacients with type 2 diabete mellitus. N England J Med 1999; 341:1127-33.
Rosenbaum P, Gimeno SG, Sanudo A, Franco LJ, Ferreira SR. Independent impact of glycemia and blood pressure in albuminuria on high-risk subjects for metabolic syndrome. Clin Nephrol 2004;61:369-76.
Rosenfield Rl, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril. 1990;53:785- 91.
Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596- 605.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4797-802.
Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development?. J Clin Endocrinol Metab 2007;92:379-85.
Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996;19:1243-8.
Scarpitta AM, Sinagra D. Polycystic ovary syndrome: an endocrine and metabolic disease. Gynecol Endocrinol 2000;14(5):392-5.
Soares EMM, Soares GM, Silva Filho JG, Melo MCL, Azevedo GD, Maranhão TMO. Causas de óbitos femininos no Rio Grande do Norte (RN) em 2002 e 2003. 51º Congresso Brasileiro de Ginecologia e Obstetrícia [VídeoCD]; 2005 ; 22-26 Nov; Rio de Janeiro. Anais. Rio de Janeiro: Tv MED; 2005.
Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Endocrinologia e Metabologia; Sociedade Brasileira de Diabetes; Sociedade Brasileira de Estudos da Obesidade. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol 2005;84 Suppl 1:1-28.
Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. J Clin Endocrinol Metab 2002;87:2013-7.
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181.
Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592-6.
Tarchini R, Bottini E, Botti P, Marseglia CD, Talassi E, Baraldi O et al. Type 2 diabetic nephropathy: clinical course and prevention proposals. G Ital Nefrol 2005;22 Suppl 31:S15-9.
Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007;3:103-11.
Vrbikova J, Vondra K, Cibula D, Dvorakova K, Stanicka S, Sramkova D, Sindelka G, Hill M, Bendlova B, Skrha J . Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005;20:3328-32.
Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6.
Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005;111:1370-6.
WHO. Obesity preventing and managing the global epidemic. Report of a WHO consultation on obesity. 1997; Geneva 3–5 June.
Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-90.
Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22;Suppl 3:25-30.